DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Torsemide (Torsemide) - Summary



Torsemide Injection is a diuretic of the pyridine-sulfonylurea class.

TORSEMIDE (Torsemide) is indicated for the following:

See all Torsemide indications & dosage >>


Published Studies Related to Torsemide

Torsemide versus furosemide after continuous renal replacement therapy due to acute renal failure in cardiac surgery patients. [2005]
Diuretic therapy in ARF (acute renal failure) is mainly done with loop diuretics, first of all furosemide... Serum creatinine and blood urea nitrogen elimination were less pronounced in the furosemide group.

more studies >>

Clinical Trials Related to Torsemide

Bioavailability Study of Torsemide Tablets Under Fed Conditions [Completed]
To compare the single-dose bioavailability of Torsemide tablets with Demadex

Bioavailability Study of Torsemide Tablets Under Fasting Conditions [Completed]
To compare the single-dose bioavailability of Torsemide tablets with Demadex

Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure. [Completed]
Torasemide is a loop diuretic (pyridine-sulfonylurea)with a wide experience in the treatment of oedema associated to heart failure, kidney or liver disease and either in the treatment of arterial hypertension (alone or combined with other anti-hypertensive drugs). It has been developed a new formulation of Torasemide (Torasemide prolonged release). The aim of this trial is to study the effects of Torasemide prolonged released in comparison with furosemide, in the reduction of myocardial fibrosis in patients with chronic heart failure (Class II-IV of the New York Heart Association Classification.

The Impact of TORasemide oN hemodynAmic and Neurohormonal Stress, and carDiac remOdeling in Heart Failure [Not yet recruiting]
The aim of the study is to compare the effects of torasemide and furosemide on clinical and biochemical parameters of hemodynamic and neurohormonal compensation and myocardial remodeling in patients with chronic heart failure with indications for use of loop diuretics. The study protocol 100 patients with heart failure NYHA (New York Heart Association) II-IV (stable or exacerbation aligned cardiopulmonary at the time of enrollment, with a fixed-dose loop diuretics]) treated with optimal medical therapy as clinically indicated for use loop diuretics. Patients will be randomized to treatment with furosemide and torasemide (randomization 1 : 1). After randomization, furosemide will continue in its current fixed-dose or will be replaced by equipotential dose of torasemide (4: 1). The minimal follow-up of patients in the study will be at least six months.

Investigator Initiated Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics. [Not yet recruiting]
Study hypothesis is that the time from randomization to the increase of natriuresis (%), time to standardization of natriuresis daily profile, blood pressure profile and the percentage reduction of central hemodynamic parameters will be relatively changed over the study period by more than 15%.

more trials >>

Reports of Suspected Torsemide Side Effects

Renal Failure Acute (58)Hypotension (40)Vomiting (34)Nausea (26)Drug Interaction (25)Diarrhoea (25)Dyspnoea (24)Fallot's Tetralogy (24)Maternal Exposure During Pregnancy (21)Hypertensive Crisis (19)more >>

Page last updated: 2006-01-31

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017